keyword
MENU ▼
Read by QxMD icon Read
search

Breast chemotherapy adjuvant and primary

keyword
https://www.readbyqxmd.com/read/28243896/breast-cancer-specific-survival-in-patients-with-lymph-node-positive-hormone-receptor-positive-invasive-breast-cancer-and-oncotype-dx-recurrence-score-results-in-the-seer-database
#1
Megan C Roberts, Dave P Miller, Steven Shak, Valentina I Petkov
PURPOSE: The Oncotype DX(®) Breast Recurrence Score™ (RS) assay is validated to predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients with lymph node-positive (LN+), hormone receptor-positive (HR+), HER2-negative BC. We assessed 5-year BC-specific survival (BCSS) in LN+ patients with RS results in SEER databases. METHODS: In this population-based study, BC cases in SEER registries (diagnosed 2004-2013) were linked to RS results from assays performed by Genomic Health (2004-2014)...
February 27, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28228661/feasibility-of-an-exercise-intervention-for-fatigued-breast-cancer-patients-at-a-community-based-cardiac-rehabilitation-program
#2
Stefanie De Jesus, Lyndsay Fitzgeorge, Karen Unsworth, David Massel, Neville Suskin, Harry Prapavessis, Michael Sanatani
PURPOSE: Exercise is beneficial to quality of life after cancer treatment, yet few cancer survivors meet exercise guidelines. Our study sought to determine the feasibility of an oncology rehabilitation exercise program embedded within a cardiac rehabilitation program. METHODS: Patients who rated their fatigue >4/10 after completion of adjuvant chemotherapy for breast cancer were screened for eligibility and the outcomes were assessed (Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Breast [FACT-B], Edmonton Symptom Assessment System, body composition, stress test, and physical activity measurement [accelerometer])...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28223032/-primary-breast-sarcomas-about-30%C3%A2-cases-treated-at-salah-azaiez-institute-in-tunisia
#3
O El Amine Elhadj, M Nasri, S Thabet, J Ben Hassouna, A Goucha, K Rahal, A Elmay, A Gamoudi
PURPOSE: To identify retrospectively prognostic factors of primary breast sarcoma and review its treatment modalities. MATERIALS AND METHODS: This is a descriptive study on 30 cases of primary breast sarcoma. We carried out a univariate and multivariate analysis correlating clinical, pathological and therapeutic parameters with disease-free survival and overall survival. RESULTS: The mean age was 46.8 years. The mean tumour size was 10cm...
February 17, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28217830/relationship-between-alcohol-metabolism-and-chemotherapy-induced-emetic-events-in-breast-cancer-patients
#4
Toshitaka Uomori, Yoshiya Horimoto, Kaoru Mogushi, Joe Matsuoka, Mitsue Saito
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) can negatively affect quality of life and treatment compliance in breast cancer patients. Habitual alcohol consumption reportedly shows an inverse correlation with CINV, though the underlying mechanism is unknown. Acetaldehyde dehydrogenase 2 (ALDH2), one of the two ALDH isozymes, is reportedly the major factor among several genetic polymorphisms possibly affecting alcohol metabolism. More than 40% of Japanese have ALDH2 mutations, while almost all Westerners have the wild type...
February 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28215665/11-years-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-early-breast-cancer-final-analysis-of-the-herceptin-adjuvant-hera-trial
#5
David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, Marion Procter, Aron Goldhirsch, Evandro de Azambuja, Gilberto Castro, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Nedal Al-Sakaff, Sabine Lauer, Eleanor McFadden, Brian Leyland-Jones, Richard Bell, Mitch Dowsett, Christian Jackisch
BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of comparing observation with two durations of trastuzumab treatment at a median follow-up of 11 years, for patients enrolled in the HERA (HERceptin Adjuvant) trial. METHODS: HERA (BIG 1-01) is an international, multicentre, open-label, phase 3 randomised trial of 5102 women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries between Dec 7, 2001, and June 20, 2005...
February 16, 2017: Lancet
https://www.readbyqxmd.com/read/28199174/role-of-troponins-i-and-t-and-n-terminal-prohormone-of-brain-natriuretic-peptide-in-monitoring-cardiac-safety-of-patients-with-early-stage-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-receiving-trastuzumab-a-herceptin-adjuvant-study-cardiac
#6
Dimitrios Zardavas, Thomas M Suter, Dirk J Van Veldhuisen, Jutta Steinseifer, Johannes Noe, Sabine Lauer, Nedal Al-Sakaff, Martine J Piccart-Gebhart, Evandro de Azambuja
Purpose Women receiving trastuzumab with chemotherapy are at risk for trastuzumab-related cardiac dysfunction (TRCD). We explored the prognostic value of cardiac markers (troponins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline susceptibility to develop TRCD. We examined whether development of cardiac end points or significant left ventricular ejection fraction (LVEF) drop was associated with markers' increases. Patients and Methods Cardiac marker assessments were coupled with LVEF measurements at different time points for 533 patients from the Herceptin Adjuvant (HERA) study who agreed to participate in this study...
March 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28187025/de-novo-upper-extremity-lymphedema-after-elective-hand-surgery-in-breast-cancer-survivors
#7
Heather L Baltzer, Jamison Harvey, Paige M Fox, Steven L Moran
BACKGROUND: The safety of elective hand surgery in breast cancer (BC) survivors is controversial because of concerns of developing upper extremity lymphedema. This study aimed to evaluate the risk of developing lymphedema after elective hand surgery among patients that underwent ipsilateral axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), and/or radiation therapy (RT). METHOD: A retrospective cohort of BC patients treated with ALND, SLNB, and/or RT was identified (1997-2012)...
February 10, 2017: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/28174294/trastuzumab-in-human-epidermal-growth-factor-receptor-2-positive-early-breast-cancer-results-of-a-prospective-noninterventional-study-on-routine-treatment-between-2006-and-2012-in-germany
#8
Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Stella Keitel, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-Schwickardi
PURPOSE: Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies. PATIENTS AND METHODS: Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy...
February 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28164759/neoadjuvant-therapy-for-her2-positive-breast-cancer
#9
Rachel Wuerstlein, Nadia Harbeck
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and -depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates in the HER2-positive subgroup of breast cancer do reach now more than 75% with the introduction of first adjvuant and later neoadjuvant HER2-targeted therapies over the last 15 years...
February 2, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28159005/the-women-s-wellness-after-cancer-program-a-multisite-single-blinded-randomised-controlled-trial-protocol
#10
Debra Anderson, Charrlotte Seib, Dian Tjondronegoro, Jane Turner, Leanne Monterosso, Amanda McGuire, Janine Porter-Steele, Wei Song, Patsy Yates, Neil King, Leonie Young, Kate White, Kathryn Lee, Sonj Hall, Mei Krishnasamy, Kathy Wells, Sarah Balaam, Alexandra L McCarthy
BACKGROUND: Despite advances in cancer diagnosis and treatment have significantly improved survival rates, patients post-treatment-related health needs are often not adequately addressed by current health services. The aim of the Women's Wellness after Cancer Program (WWACP), which is a digitised multimodal lifestyle intervention, is to enhance health-related quality of life in women previously treated for blood, breast and gynaecological cancers. METHODS: A single-blinded, multi-centre randomized controlled trial recruited a total of 330 women within 24 months of completion of chemotherapy (primary or adjuvant) and/or radiotherapy...
February 3, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28156643/pilot-study-of-minocycline-for-the-prevention-of-paclitaxel-associated-neuropathy-accru-ru221408i
#11
Travis J Dockter, Patricia J Zekan, Briant Fruth, Kathryn Jean Ruddy, Lauren E Ta, Todor Dentchev, Nguyet Le-Lindqwister, William M Sikov, Charles L Loprinzi
220 Background: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Preliminary animal data suggest that minocycline may be effective for the prevention of chemotherapy-induced neurotoxicity. The purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and P-APS. METHODS: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28155054/benefit-of-adjuvant-chemotherapy-with-or-without-trastuzumab-in-pt1ab-node-negative-human-epidermal-growth-factor-receptor-2-positive-breast-carcinomas-results-of-a-national-multi-institutional-study
#12
Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean M Classe, Monique Cohen, Eric Lambaudie, Fabien Reyal, Christophe Scherer, Xavier Muracciole, Pierre E Colombo, Sylvia Giard, Roman Rouzier, Richard Villet, Nicolas Chopin, Emile Darai, Jean R Garbay, Pierre Gimbergues, Laura Sabiani, Charles Coutant, Renaud Sabatier, François Bertucci, Jean M Boher, Gilles Houvenaeghel
PURPOSE: Benefit of adjuvant trastuzumab-based chemotherapy for node-positive and/or >1 cm human epidermal growth factor receptor 2-positive (HER2+) breast carcinomas has been clearly demonstrated in randomized clinical trials. Yet, evidence that adjuvant chemotherapy with or without trastuzumab is effective in pT1abN0 HER2+ tumors is still limited. The primary objective of this study was to investigate the impact of adjuvant chemotherapy ± trastuzumab on outcome in this subpopulation...
April 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28152707/chemotherapy-costs-associated-with-receipt-of-the-adoption-of-oncotype-dx-in-early-stage-breast-cancer-within-the-seer-medicare-population
#13
Xiaojuan Mi, Shelby D Reed, Gary H Lyman, Lesley H Curtis
32 Background: The Oncotype DX (ODX) multigene assay has been previously suggested to result in an overall reduction in the use of adjuvant chemotherapy and associated costs for women with early stage, estrogen receptor (ER)-positive breast cancer. However, the association between adoption of ODX and chemotherapy costs has only previously been considered in theoretical models and has not been examined using actual patient outcomes in real world clinical practice. METHODS: Retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) -Medicare data of the association between overall and chemotherapy-specific costs associated with adoption of ODX testing in patients diagnosed with invasive, non-metastatic, ER-positive breast cancer between 2005 and 2009...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152687/feasibility-acceptability-and-efficacy-of-a-proactive-telephone-intervention-to-improve-toxicity-management-during-chemotherapy
#14
Cassandra McKay, Heekyung Han, Sonal Gandhi, Nicole Beatrice Laferriere, Clare Atzema, Kelvin K Chan, Doris Howell, Vishal Kukreti, Yvonne Leung, Aliya Pardhan, Sandy Mitchell, Marla Nayer, Mark Pasetka, Jane Yao, Erin Redwood
105 Background: Chemotherapy (chemo) is associated with a significant risk of toxicity, which often peaks between ambulatory visits. Consequently, effective remote symptom management support is essential to optimize self-management and resource use, including emergency department visits and hospitalizations (ED+H) during chemo. The aim of this study was to examine the feasibility, acceptability and effects of a telephone management intervention on symptomatic toxicity and resource use during chemo for early stage breast cancer (EBC)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28133212/-use-of-pegfilgrastim-in-adjuvant-and-neoadjuvant-chemotherapy-for-breast-cancer
#15
Noriko Abe, Tohru Ohtake, Sadahiko Abe, Keita Aoto, Maiko Okano, Kazunoshin Tachibana, Seiich Takenoshita
We assessed the incidence of febrile neutropenia(FN), infection, and relative dose intensity(RDI)with or without the use of pegfilgrastim in breast cancer patients receiving adjuvant or neoadjuvant chemotherapy. Twenty-five patients received 4 cycles of FEC(5-FU 500mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 100 mg/m2 q3w)followed by 4 cycles of docetaxel(75mg/m2 q3w). Ten patients were administered pegfilgrastim as primary prophylaxis throughout all cycles of chemotherapy, and 15 patients were not...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133208/-a-case-of-primary-acinic-cell-carcinoma-acc-of-the-breast
#16
Hiroshi Kawai, Ryoma Sugimoto, Norichika Iga, Hirokuni Ikeda, Ryosuke Yoshida, Naohisa Waki, Masahiro Ishizaki, Hideyuki Nishi, Kazuki Yamashita
A49 -year-old woman presented with a 3.5 cm mass in her right breast. Mammography revealed a lobular mass with poorly defined margins and no microcalcification. Ultrasonography showed a hypoechoic mass with an irregular margin. The tumor was diagnosed as breast carcinoma using a core needle biopsy. The patient underwent a modified radical mastectomy with sentinel lymph node biopsy, and received adjuvant chemotherapy. The tumor consisted of 2 types of carcinoma. The center of the tumor was solid-tubular carcinoma, and the periphery was acinic cell carcinoma(ACC)...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28129608/an-ovarian-mass-after-breast-cancer-metachronous-carcinoma-or-metastasis-a-case-report
#17
Georgios-Marios Makris, Alexandros Marinelis, Marco-Johannes Battista, Charalampos Chrelias, Nikolaos Papantoniou
INTRODUCTION: Differentiating between primary and secondary ovarian cancer can be a difficult task. In hereditary conditions breast malignancies and primary ovarian cancer often coexist. PRESENTATION OF CASE: We present a 45-year-old patient with an ovarian mass two years after the diagnosis of a lobular, triple negative breast carcinoma. There was concern whether the lesion represented a metachronous ovarian cancer or a metastasis of the lobular carcinoma. The final histological examination showed a metastatic lesion, deriving from the lobular breast carcinoma, as evidenced by the immunohistochemical profile; nevertheless, there were changes in hormonal receptor expression in the metastatic lesion compared to the primary, triple negative tumor...
December 30, 2016: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28123851/the-fate-of-brca1-related-germline-mutations-in-triple-negative-breast-tumors
#18
Vassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, Paraskevi Apostolou, Eleftheria Tsolaki, Georgios Lazaridis, Kyriaki Manoussou, Flora Zagouri, Dimitrios Pectasides, Ioannis Vlachos, Ioannis Tikas, Sotiris Lakis, Irene Konstantopoulou, George Pentheroudakis, Helen Gogas, Pavlos Papakostas, Christos Christodoulou, Dimitrios Bafaloukos, Evangelia Razis, Vasilios Karavasilis, Christina Bamias, Drakoulis Yannoukakos, George Fountzilas
The preservation of pathogenic BRCA1/2 germline mutations in tumor tissues is usually not questioned, while it remains unknown whether these interact with somatic genotypes for patient outcome. Herein we compared germline and tumor genotypes in operable triple-negative breast cancer (TNBC) and evaluated their combined effects on prognosis. We analyzed baseline germline and primary tumor genotype data obtained by Sanger and Next Generation Sequencing in 194 TNBC patients. We also performed multiple tests interrogating the preservation of germline mutations in matched tumors and breast tissue from carriers with available material...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28122895/21-gene-recurrence-score-and-locoregional-recurrence-in-node-positive-er-positive-breast-cancer-treated-with-chemo-endocrine-therapy
#19
Eleftherios P Mamounas, Qing Liu, Soonmyung Paik, Frederick L Baehner, Gong Tang, Jong-Hyeon Jeong, S Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
BACKGROUND: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node-negative, estrogen receptor (ER)-positive breast cancer. We evaluated the association between RS and LRR in node-positive, ER-positive patients treated with adjuvant chemotherapy plus tamoxifen in National Surgical Adjuvant Breast and Bowel Project B-28. METHODS: B-28 compared doxorubicin/cyclophosphamide (AC X 4) with AC X 4 followed by paclitaxel X 4. Tamoxifen was given to patients age 50 years or older and those younger than age 50 years with ER-positive and/or progesterone receptor-positive tumors...
January 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28122890/efficacy-of-reduced-dose-of-pegfilgrastim-in-japanese-breast-cancer-patients-receiving-dose-dense-doxorubicin-and-cyclophosphamide-therapy
#20
Yoshio Mizuno, Hiromi Fuchikami, Naoko Takeda, Masaru Iwai, Kazuhiko Sato
BACKGROUND: This retrospective study aimed to evaluate the efficacy of a 3.6-mg dose of pegfilgrastim for primary prophylaxis in Japanese breast cancer patients receiving dose-dense chemotherapy. METHODS: Patients treated with adjuvant or neoadjuvant chemotherapy for early-stage breast cancer at the Tokyo-West Tokushukai Hospital were included in this analysis. Because 6 mg pegfilgrastim has not yet been approved for use in Japan, we compared the outcomes of a dose-dense doxorubicin and cyclophosphamide regimen plus 3...
January 2017: Japanese Journal of Clinical Oncology
keyword
keyword
43929
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"